Literature DB >> 17891660

Methamphetamine users in the psychiatric emergency services: a case-control study.

Jagoda Pasic1, Joan E Russo, Richard K Ries, Peter P Roy-Byrne.   

Abstract

The purpose of this study is to examine the sociodemographic, clinical, and service use characteristics of patients with positive methamphetamine (MA) urine toxicology and compare with non-MA users seen in an urban Psychiatric Emergency Services (PES). One hundred twenty patient charts were extracted for demographics, mode of arrival, clinical information, medication treatment of MA-intoxication, and disposition. Compared with non-MA patients, MA patients were significantly younger, male, referred by police, with cardiac symptoms, psychosis, dysphoria, past substance use, and were less likely to have a diagnosis of Schizophrenia, a past psychiatric history/hospitalization, and a history of suicide attempts. Subsequent hospitalization rates did not differ. MA patients treated with medications more readily accepted the referral to chemical dependency treatment. This study shows that hypertension and tachycardia upon arrival to the PES, symptoms of dysphoria and psychosis, past substance use and not having the diagnosis of Schizophrenia are all related to methamphetamine use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17891660     DOI: 10.1080/00952990701522732

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  13 in total

1.  Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Psychopharmacology (Berl)       Date:  2010-11-12       Impact factor: 4.530

2.  High Resource Utilization of Psychiatric Emergency Services by Methamphetamine Users.

Authors:  Brian R Schultz; Brett Y Lu; Jane M Onoye; Tara P Toohey
Journal:  Hawaii J Med Public Health       Date:  2018-12

3.  Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.

Authors:  Craig R Rush; William W Stoops; Joshua A Lile; Paul E A Glaser; Lon R Hays
Journal:  Pharmacol Biochem Behav       Date:  2011-07-23       Impact factor: 3.533

4.  Reaction time variability and related brain activity in methamphetamine psychosis.

Authors:  Catherine Fassbender; Tyler A Lesh; Stefan Ursu; Ruth Salo
Journal:  Biol Psychiatry       Date:  2014-08-07       Impact factor: 13.382

5.  Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole.

Authors:  Rajkumar J Sevak; Andrea R Vansickel; William W Stoops; Paul E A Glaser; Lon R Hays; Craig R Rush
Journal:  J Clin Psychopharmacol       Date:  2011-08       Impact factor: 3.153

6.  Acute buspirone dosing enhances abuse-related subjective effects of oral methamphetamine.

Authors:  Erika Pike; William W Stoops; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2016-09-30       Impact factor: 3.533

Review 7.  Treatment for amphetamine withdrawal.

Authors:  Steven J Shoptaw; Uyen Kao; Keith Heinzerling; Walter Ling
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

8.  Predictors of methamphetamine psychosis: history of ADHD-relevant childhood behaviors and drug exposure.

Authors:  Ruth Salo; Catherine Fassbender; Ana-Maria Iosif; Stefan Ursu; Martin H Leamon; Cameron Carter
Journal:  Psychiatry Res       Date:  2013-07-26       Impact factor: 3.222

9.  Buspirone maintenance does not alter the reinforcing, subjective, and cardiovascular effects of intranasal methamphetamine.

Authors:  Anna R Reynolds; Justin C Strickland; William W Stoops; Joshua A Lile; Craig R Rush
Journal:  Drug Alcohol Depend       Date:  2017-09-22       Impact factor: 4.492

10.  A Study of the Prevalence of Psychiatric Disorders in Patients with Methamphetamine-Induced Psychosis.

Authors:  Mahin Eslami-Shahrbabaki; Alireza Fekrat; Shahrzad Mazhari
Journal:  Addict Health       Date:  2015 Winter-Spring
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.